Sunrise pharmaceutical dextroamphetamine?

What is dextroamphetamine?
Dextroamphetamine is a central nervous system stimulant used to treat attention‑deficit/hyperactivity disorder (ADHD) and narcolepsy. It works by increasing the activity of dopamine and norepinephrine in the brain, which improves focus, alertness, and energy. The drug is available only by prescription in the United States.

Is there a Sunrise Pharmaceutical dextroamphetamine product?
No publicly available information lists a dextroamphetamine formulation marketed or manufactured by Sunrise Pharmaceutical. A search of the U.S. Food and Drug Administration’s drug database, the Orange Book, and Sunrise Pharmaceutical’s own website yields no entries for dextroamphetamine under that company’s name.

What other companies sell dextroamphetamine?
Several manufacturers supply dextroamphetamine, including Pfizer (marketed as Adderall), Eli Lilly (marketed as Focalin), and several generic producers such as Teva and Mylan. These products are sold under brand names or as generic tablets and capsules.

How can you confirm a manufacturer’s legitimacy?
Check the FDA’s “Approved Drug Products with Therapeutic Equivalence Evaluations” list (Orange Book) and the Drug Enforcement Administration’s drug list for the active ingredient. Verify the manufacturer’s name, address, and product labeling on the FDA’s “Drug Enforcement Administration’s Drug Enforcement Administration’s” database.

Are there generic dextroamphetamine options?
Yes. Generic versions contain the same active ingredient and are approved by the FDA as therapeutically equivalent to the brand‑name products. They are typically cheaper and widely available in pharmacies.

What should a patient consider before using dextroamphetamine?
Patients should discuss medical history, especially cardiovascular conditions, with a prescriber. Common side effects include insomnia, decreased appetite, and increased heart rate. Long‑term use may lead to dependence or tolerance, and the drug is classified as a Schedule II controlled substance.

Can Sunrise Pharmaceutical enter the dextroamphetamine market?
If Sunrise Pharmaceutical intends to launch a new dextroamphetamine product, it would need to complete pre‑clinical studies, submit an Investigational New Drug (IND) application, and eventually obtain New Drug Application (FDA) approval. The timeline from IND to approval typically spans 3–5 years, depending on study results and regulatory review.

Where can you find more reliable information?
Consult the FDA’s drug database, the Centers for Disease Control and Prevention’s prescription drug monitoring program, or the National Institutes of Health’s MedlinePlus for detailed drug information and manufacturer details.